AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go head-to-head with the AstraZeneca unit's market-leading therapies Ultomiris and Soliris.